Gilead stock rises after settling Biktarvy patent disputes

Investing.com -- Gilead Sciences Inc. (NASDAQ: GILD) stock rose 4.5% Monday after the company announced it had settled patent disputes with multiple generic drugmakers over its HIV treatment Biktarvy.

The biopharmaceutical company reached settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd., who had filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of the medication. According to an SEC filing, the agreements ensure no generic entry for Biktarvy in the United States is expected before April 1, 2036, providing Gilead with extended market exclusivity for one of its key products.

Biktarvy is a complete HIV treatment regimen in a single tablet containing bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg). The settlement agreements are subject to standard acceleration provisions, the company noted.

The resolution of these patent disputes removes a significant uncertainty for Gilead, potentially securing over a decade of additional exclusivity for Biktarvy, which has been a major revenue driver for the company. The settlement helps Gilead protect its intellectual property while providing clarity on when generic competition might enter the market.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Breeze Acquisition Corp. II gets Nasdaq notice for late 10-Q filings
• Gossamer Bio raises up to $250M in private placement for PAH drug